Combination of very low energy diets and pharmacotherapy in the treatment of obesity: meta-analysis of published data

Anti-obesity drugs: past, present and future

(2012) R. J. Rodgers et al.   Disease Models & Mechanisms

Emerging pharmacotherapy for obesity

(2011) Louis J Aronne et al.   EXPERT OPINION ON EMERGING DRUGS

Medications for Weight Reduction

(2011) George A. Bray   MEDICAL CLINICS OF NORTH AMERICA

Pharmacologic management of obesity

(2011) Robert F. Kushner   PEDIATRIC BLOOD & CANCER

“Weighing in” on synergy: Preclinical research on neurohormonal anti-obesity combinations

(2010) Jonathan D. Roth et al.   BRAIN RESEARCH

Pharmacologic Therapies for Obesity

(2010) Lee M. Kaplan   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

(2010) L J Aronne et al.   INTERNATIONAL JOURNAL OF OBESITY

Taranabant no longer developed as an antiobesity agent

(2010) Linda Koch   Nature Reviews Endocrinology

Pharmacotherapy for obesity

(2009) Mingfang Li et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes

(2009) M. S. Kipnes et al.   DIABETES OBESITY & METABOLISM

Successful Weight-loss Maintenance in Relation to Method of Weight Loss

(2008) Angela Marinilli Pinto et al.   Obesity

Rational Design of a Combination Medication for the Treatment of Obesity

(2008) Frank L. Greenway et al.   Obesity